DGAP-News: EVOTEC PARTICIPATES IN EXSCIENTIA'S FINANCING ROUND
$ 60 M FINANCING ROUND INCLUDES NEW INVESTOR NOVO HOLDINGS AS WELL AS EXISTING INVESTORS EVOTEC, BRISTOL MYERS SQUIBB, AND GT HEALTHCARE CAPITAL
DGAP-News: Evotec SE / Key word(s): Miscellaneous EVOTEC PARTICIPATES IN EXSCIENTIA'S FINANCING ROUND 26.05.2020 / 07:30 The issuer is solely responsible for the content of this announcement.
Hamburg, Germany, 26 May 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has participated in the Series C funding round of Exscientia, the world-leading Artificial Intelligence ("AI")-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors' consortium consisting of Evotec, Bristol Myers Squibb, and GT Healthcare Capital also participating in the round.
26.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | [email protected] |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1055075 |
End of News | DGAP News Service |
|
1055075 26.05.2020